More in vivo experiments to better understand how IMP1 reduces the metastatic potential of the primary breast tumor and high throughput screening of small compounds that increase IMP1 expression in late mammary carcinomas will be important avenues for future study. Here, IGF2BP1 is linked to breast carcinoma.